Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Systemic Immune Inflammation Index as High-Risk Retinoblastoma Survival Predictor.

Created on 28 Aug 2026

Authors

Imanuel Yulius Malino, Novie Amelia Chozie, Muzal Kadim, Antonius Hocky Pudjiadi, Eddy Supriyadi, Hikari Ambara Sjakti

Published in

Asian Pacific journal of cancer prevention : APJCP. Volume 27. Issue 8. Pages 2959-2967. Aug 01, 2026. Epub Aug 01, 2026.

Abstract

To determine the ability of SII as a predictor of five-year survival in high-risk Rb.
A retrospective cohort study, from August to September 2024 at Dr. Cipto Mangunkusumo Hospital.
We conducted the analysis on 157 high-risk Rb subjects between 2016 and 2024. The cut-off point based on the Receiver Operating Characteristic (ROC) curve, with the maximum Youden index value, was identified at an SII of 351.72. The five-year overall survival (OS) and event-free survival (EFS) were 35.9% (SE ± 4.8%) and 32.1% (SE ± 4.8%), respectively. The median OS and EFS were 17 months and 16 months, respectively. High baseline SII (≥351.72) was associated with five years median OS of 11 months (SE ± 9.38; 95% CI: 9.16-12.84), a survival rate of 14.5% (SE ± 4.7 High SII (SII ≥351.72). Both baseline and serial high SII were associated with poorer 60-month overall survival in high-risk retinoblastoma (aHR 1.94; 95% CI, 1.11-3.40; p=0.02 and aHR 3.59; 95% CI, 2.49-5.19; p<0.01, respectively).  Conclusion: SII may predict survival in high-risk Rb.

PMID:
42663217
Bibliographic data and abstract were imported from PubMed on 28 Aug 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 5
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement